The iron chelator, Dp44mT, effectively inhibits human oral squamous cell carcinoma cell growth in vitro and in vivo

International Journal of Molecular Sciences

Volumn 17, Issue 9, 2016, Pages

  Lee, Jehn Chuan ^a,b   Chiang, Kun Chun ^c   Feng, Tsui Hsia ^d   Chen, Yu Jen ^a   Chuang, Sung Ting ^d   Tsui, Ke Hung ^c   Chung, Li Chuan ^e   Juang, Horng Heng ^c,d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEDICAL COLLEGE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e NURSING AND MANAGEMENT COLLEGE   (Taiwan)

Author keywords

Deferasirox; DFO; Maspin; NDRG1; NDRG3

Indexed keywords

BETA ACTIN; CYCLIN D1; DEFERASIROX; DEFEROXAMINE; DP44MT; IRON CHELATING AGENT; MASPIN; NDRG1 PROTEIN; NDRG2 PROTEIN; NDRG3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DI-2-PYRIDYLKETONE-4,4-DIMETHYL-3-THIOSEMICARBAZONE; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; NDRG3 PROTEIN, HUMAN; NERVE PROTEIN; SERINE PROTEINASE INHIBITOR; SERPIN-B5; SIGNAL PEPTIDE; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; MRNA EXPRESSION ASSAY; NONHUMAN; OECM 1 CELL; ORAL CANCER CELL LINE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SAS CELL; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; MALE; METABOLISM; MOUTH NEOPLASMS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; IRON CHELATING AGENTS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NERVE TISSUE PROTEINS; SERPINS; THIOSEMICARBAZONES;

EID: 85016125319     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17091435     Document Type: Article

References (45)

1. Johnson, N.W.; Jayasekara, P.; Amarasinghe, A.A. Squamous cell carcinoma and precursor lesions of the oral cavity: Epidemiology and aetiology. Periodontol. 2000 2011, 57, 19-37. [CrossRef] [PubMed]
2. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87-108. [CrossRef] [PubMed]
3. Simard, E.P.; Torre, L.A.; Jemal, A. International trends in head and neck cancer incidence rates: Differences by country, sex and anatomic site. Oral Oncol. 2014, 50, 387-403. [CrossRef] [PubMed]
4. Warnakulasuriya, S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009, 45, 309-316. [CrossRef] [PubMed]
5. Kalinowski, D.S.; Richardson, D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57, 547-583. [CrossRef] [PubMed]
6. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA 2006, 103, 14901-14906. [CrossRef] [PubMed]
7. Lui, G.Y.; Obeidy, P.; Ford, S.J.; Tselepis, C.; Sharp, D.M.; Jansson, P.J.; Kalinowski, D.S.; Kovacevic, Z.; Lovejoy, D.B.; Richardson, D.R. The iron chelator, deferasirox, as a novel strategy for cancer treatment: Oral activity against human lung tumor xenografts and molecular mechanism of action. Mol. Pharmacol. 2013, 83, 179-190. [CrossRef] [PubMed]
8. Yu, Y.; Gutierrez, E.; Kovacevic, Z.; Saletta, F.; Obeidy, P.; Suryo Rahmanto, Y.; Richardson, D.R. Iron chelators for the treatment of cancer. Curr. Med. Chem. 2012, 19, 2689-2702. [CrossRef] [PubMed]
9. Yuan, J.; Lovejoy, D.B.; Richardson, D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment. Blood 2004, 104, 1450-1458. [CrossRef] [PubMed]
10. Fu, D.; Richardson, D.R. Iron chelation and regulation of the cell cycle: 2 Mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 2007, 110, 752-761. [CrossRef] [PubMed]
11. Yu, Y.; Richardson, D.R. Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J. Biol. Chem. 2011, 286, 15413-15427. [CrossRef] [PubMed]
12. Melotte, V.; Qu, X.; Ongenaert, M.; van Criekinge, W.; de Bruine, A.P.; Baldwin, H.S.; van Engeland, M. The N-myc downstream regulated gene (NDRG) family: Diverse functions, multiple applications. FASEB J. 2010, 24, 4153-4166. [CrossRef] [PubMed]
13. Qu, X.; Zhai, Y.; Wei, H.; Zhang, C.; Xing, G.; Yu, Y.; He, F. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell. Biochem. 2002, 229, 35-44. [CrossRef] [PubMed]
14. Yang, X.; An, L.; Li, X. NDRG3 and NDRG4, two novel tumor-related genes. Biomed. Pharmacother. 2013, 67, 681-684. [CrossRef] [PubMed]
15. Dos Santos, M.; da Cunha Mercante, A.M.; Nunes, F.D.; Leopoldino, A.M.; de Carvalho, M.B.; Gazito, D.; Lopez, R.V.; Chiappini, P.B.; de Carvalho Neto, P.B.; Fukuyama, E.E. et al. Prognostic significance of NDRG1 expression in oral and oropharyngeal squamous cell carcinoma. Mol. Biol. Rep. 2012, 39, 10157-10165. [CrossRef] [PubMed]
16. Lee, J.C.; Chung, L.C.; Chen, Y.J.; Feng, T.H.; Juang, H.H. N-myc downstream-regulated gene 1 downregulates cell proliferation, invasiveness, and tumorigenesis in human oral squamous cell carcinoma. Cancer Lett. 2014, 355, 242-252. [CrossRef] [PubMed]
17. Furuta, H.; Kondo, Y.; Nakahata, S.; Hamasaki, M.; Sakoda, S.; Morishita, K. NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma. Biochem. Biophys. Res. Commun. 2010, 391, 1785-1791. [CrossRef] [PubMed]
18. Kovacevic, Z.; Chikhani, S.; Lovejoy, D.B.; Richardson, D.R. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer. Mol. Pharmacol. 2011, 80, 598-609. [CrossRef] [PubMed]
19. Wang, J.; Yin, D.; Xie, C.; Zheng, T.; Liang, Y.; Hong, X.; Lu, Z.; Song, X.; Song, R.; Yang, H. et al. The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway. Oncotarget 2014, 5, 8478-8491. [CrossRef] [PubMed]
20. Fang, B.A.; Kovacevic, Z.; Park, K.C.; Kalinowski, D.S.; Jansson, P.J.; Lane, D.J.; Sahni, S.; Richardson, D.R. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim. Biophys. Acta 2014, 1845, 1-19. [CrossRef] [PubMed]
21. Fan, C.G.;Wang, C.M.; Tian, C.;Wang, Y.; Li, L.; Sun, W.S.; Li, R.F.; Liu, Y.G. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol. Rep. 2011, 26, 1281-1286. [PubMed]
22. Ren, G.F.; Tang, L.; Yang, A.Q.; Jiang, W.W.; Huang, Y.M. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy. Histol. Histopathol. 2014, 29, 535-542. [PubMed]
23. Wang, W.; Li, Y.; Li, Y.; Hong, A.; Wang, J.; Lin, B.; Li, R. NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth. Int. J. Cancer 2009, 124, 521-530. [CrossRef] [PubMed]
24. Bailey, C.M.; Khalkhali-Ellis, Z.; Seftor, E.A.; Hendrix, M.J. Biological functions of maspin. J. Cell. Physiol. 2006, 209, 617-624. [CrossRef] [PubMed]
25. Xia, W.; Lau, Y.K.; Hu, M.C.; Li, L.; Johnston, D.A.; Sheng, S.; El-Naggar, A.; Hung, M.C. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000, 19, 2398-2403. [CrossRef] [PubMed]
26. Yoshizawa, K.; Nozaki, S.; Kitahara, H.; Kato, K.; Noguchi, N.; Kawashiri, S.; Yamamoto, E. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. Oncol. Rep. 2011, 26, 1555-1560. [CrossRef] [PubMed]
27. Marioni, G.; Gaio, E.; Giacomelli, L.; Bertolin, A.; D’Alessandro, E.; Stramare, R.; Facco, E.; Staffieri, A.; Blandamura, S. MASPIN subcellular localization and expression in oral cavity squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 2008, 265, S97-S104. [CrossRef] [PubMed]
28. Davis, S.J.; Divi, V.; Owen, J.H.; Bradford, C.R.; Carey, T.E.; Papagerakis, S.; Prince, M.E. Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2010, 136, 1260-1266. [CrossRef] [PubMed]
29. Dionne, K.R.; Warnakulasuriya, S.; Zain, R.B.; Cheong, S.C. Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory. Int. J. Cancer 2015, 136, 503-515. [CrossRef] [PubMed]
30. Choi, S.; Myers, J.N. Molecular pathogenesis of oral squamous cell carcinoma: Implications for therapy. J. Dent. Res. 2008, 87, 14-32. [CrossRef] [PubMed]
31. Huang, S.F.; Cheng, S.D.; Chuang, W.Y.; Chen, I.H.; Liao, C.T.; Wang, H.M.; Hsieh, L.L. Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. World J. Surg. Oncol. 2012, 10, 40. [CrossRef] [PubMed]
32. Chen, Z.; Zhang, D.; Yue, F.; Zheng, M.; Kovacevic, Z.; Richardson, D.R. The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J. Biol. Chem. 2012, 287, 17016-17028. [CrossRef] [PubMed]
33. Lescoat, G.; Chantrel-Groussard, K.; Pasdeloup, N.; Nick, H.; Brissot, P.; Gaboriau, F. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: A possible relationship with polyamine metabolism. Cell Prolif. 2007, 40, 755-767. [CrossRef] [PubMed]
34. Ohyashiki, J.H.; Kobayashi, C.; Hamamura, R.; Okabe, S.; Tauchi, T.; Ohyashiki, K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci. 2009, 100, 970-977. [CrossRef] [PubMed]
35. Lui, G.Y.; Kovacevic, Z.; Menezes, S.V.; Kalinowski, D.S.; Merlot, A.M.; Sahni, S.; Richardson, D.R. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: Inhibition of constitutive and interleukin 6-induced activation by iron depletion. Mol. Pharmacol. 2015, 87, 543-560. [CrossRef] [PubMed]
36. Nurtjahja-Tjendraputra, E.; Fu, D.; Phang, J.M.; Richardson, D.R. Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiency-mediated growth suppression. Blood 2007, 109, 4045-4054. [CrossRef] [PubMed]
37. Tsui, K.H.; Lin, Y.H.; Chung, L.C.; Chuang, S.T.; Feng, T.H.; Chiang, K.C.; Chang, P.L.; Yeh, C.J.; Juang, H.H. Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells. Cancer Lett. 2016, 375, 142-151. [CrossRef] [PubMed]
38. Al-Mamun, M.A.; Farid, D.M.; Ravenhil, L.; Hossain, M.A.; Fall, C.; Bass, R. An in silico model to demonstrate the effects of Maspin on cancer cell dynamics. J. Theor. Biol. 2016, 388, 37-49. [CrossRef] [PubMed]
39. Fan, L.; Iyer, J.; Zhu, S.; Frick, K.K.; Wada, R.K.; Eskenazi, A.E.; Berg, P.E.; Ikegaki, N.; Kennett, R.H.; Frantz, C.N. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res. 2001, 61, 1073-1079. [PubMed]
40. Ford, S.J.; Obeidy, P.; Lovejoy, D.B.; Bedford, M.; Nichols, L.; Chadwick, C.; Tucker, O.; Lui, G.Y.; Kalinowski, D.S.; Jansson, P.J. et al. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br. J. Pharmacol. 2013, 168, 1316-1328. [CrossRef] [PubMed]
41. Dayani, P.N.; Bishop, M.C.; Black, K.; Zeltzer, P.M. Desferoxamine (DFO)-mediated iron chelation: Rationale for a novel approach to therapy for brain cancer. J. Neurooncol. 2004, 67, 367-377. [CrossRef] [PubMed]
42. Lee, J.C.; Chung, L.C.; Chen, Y.J.; Feng, T.H.; Chen, W.T.; Juang, H.H. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells. Cancer Lett. 2015, 360, 310-318. [CrossRef] [PubMed]
43. Franken, N.A.; Rodermond, H.M.; Stap, J.; Haveman, J.; van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 2006, 1, 2315-2319. [CrossRef] [PubMed]
44. Chiang, K.C.; Yeh, C.N.; Chung, L.C.; Feng, T.H.; Sun, C.C.; Chen, M.F.; Jan, Y.Y.; Yeh, T.S.; Chen, S.C.; Juang, H.H. WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer. Sci. Rep. 2015, 5, 8686. [CrossRef] [PubMed]
45. Tsui, K.H.; Hsu, S.Y.; Chung, L.C.; Lin, Y.H.; Feng, T.H.; Lee, T.Y.; Chang, P.L.; Juang, H.H. Growth differentiation factor-15: Ap53-and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells. Sci. Rep. 2015, 5, 12870. [CrossRef] [PubMed]